Skip to main content
. Author manuscript; available in PMC: 2012 Jan 17.
Published in final edited form as: Vaccine. 2010 Nov 21;29(4):721–727. doi: 10.1016/j.vaccine.2010.11.020

Figure 1. Intranasal co-administration of LT-IIc enhances Ag-specific mucosal and systemic immune responses to AgI/II.

Figure 1

BALB/c mice were immunized intranasally on days 1, 14, and 28 with 10 μg of AgI/II in the presence or absence of 1 μg of LT-IIb or LT-IIc as a mucosal adjuvant. Samples were obtained at day 42 at the time of peak Ag-specific antibody response. Samples were measured for: (A) salivary IgA, (B) vaginal IgA, (C) serum IgA, and (D) serum IgG. Data are reported as arithmetic means; error bars denote one standard error of the mean (n = 5 or 6). Key: statistically different from mice immunized only with AgI/II at P<0.01 (**) and P<0.001 (***).